Viridian Therapeutics Launches Underwritten Public Offering of Common and Preferred Stock
Reuters
Oct 22
Viridian <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Launches Underwritten Public Offering of Common and Preferred Stock
Viridian Therapeutics Inc. has announced the commencement of an underwritten public offering of shares of its common stock and Series B non-voting convertible preferred stock. All securities in the offering will be sold by Viridian, and the company may also grant underwriters a 30-day option to purchase additional common shares. Each Series B preferred share is convertible into 66.67 shares of common stock, subject to certain ownership limits. Proceeds from the offering are intended to support commercial launch activities for veligrotug and VRDN-003, fund research and development, and provide working capital and general corporate funds. Jefferies, Leerink Partners, Evercore ISI, and Stifel are serving as joint book-running managers, with Wedbush PacGrow acting as co-manager.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251021516711) on October 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.